No data to show
XSTO
CMOTEC B
Market cap4mUSD
May 08, Last price
2.05SEK
1D
4.06%
1Q
86.36%
Jan 2017
-96.13%
IPO
-95.83%
Name
Scandinavian ChemoTech AB
Chart & Performance
P/E
—
P/S
6.99
EPS
—
Div Yield, %
—
Shrs. gr., 5y
38.09%
Rev. gr., 5y
63.85%
Revenues
7m
+132.67%
Net income
-14m
L-34.96%
CFO
-13m
L-27.88%
Profile
Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||||
Revenues | 6,566 132.67% | 2,822 496.62% | 473 865.31% | ||||||||
Cost of revenue | 1,789 | 3,735 | 3,435 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | 4,777 | (913) | (2,962) | ||||||||
NOPBT Margin | 72.75% | ||||||||||
Operating Taxes | 1,834 | ||||||||||
Tax Rate | |||||||||||
NOPAT | 4,777 | (913) | (4,796) | ||||||||
Net income | (13,717) -34.96% | (21,091) -14.19% | (24,580) 33.46% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 18,379 | 12,556 | |||||||||
BB yield | -36.60% | -24.94% | |||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 1,820 | ||||||||||
Net debt | (949) | (923) | (6,274) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (13,145) | (18,226) | (19,630) | ||||||||
CAPEX | (680) | (331) | |||||||||
Cash from investing activities | (2) | (468) | (603) | ||||||||
Cash from financing activities | 13,173 | 13,765 | 17,257 | ||||||||
FCF | 7,222 | (3,063) | (254) | ||||||||
| Balance | |||||||||||
Cash | 949 | 923 | 5,852 | ||||||||
Long term investments | 422 | ||||||||||
Excess cash | 621 | 782 | 6,250 | ||||||||
Stockholders' equity | (100,020) | (87,649) | |||||||||
Invested Capital | 5,980 | 111,051 | 101,641 | ||||||||
ROIC | 8.16% | ||||||||||
ROCE | 79.88% | ||||||||||
| EV | |||||||||||
Common stock shares outstanding | 20,655 | 18,600 | 9,969 | ||||||||
Price | 1.79 -33.70% | 2.70 -46.53% | 5.05 -70.36% | ||||||||
Market cap | 36,973 -26.38% | 50,221 -0.24% | 50,342 -65.87% | ||||||||
EV | 36,024 | 49,298 | 60,807 | ||||||||
EBITDA | 4,777 | 1,767 | (14) | ||||||||
EV/EBITDA | 7.54 | 27.90 | |||||||||
Interest | 1,403 | 1,897 | |||||||||
Interest/NOPBT | |||||||||||